Alpha 2.0
Login Register
» Authors » Thomas Steuber

Thomas Steuber

Explore the profile of Thomas Steuber including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 198
Citations 3937
Followers 0
Related Specialties
Urology
Oncology
Biochemistry
Top 10 Co-Authors
Markus Graefen
Hartwig Huland
Alexander Haese
Thorsten Schlomm
Derya Tilki
Pierre I Karakiewicz
Hans Heinzer
Lars Budaus
Philipp Mandel
Georg Salomon
Published In
Eur Urol
BJU Int
World J Urol
Eur Urol Focus
Urol Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Patient-Reported Outcome Measures and Decision Regret After Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following Radiotherapy or Focal Therapy
Falkenbach F, Hagemann J, Ambrosini F, Karakiewicz P, Tian Z, Nagaraj Y, et al.
Cancers (Basel) . 2025 Feb; 17(3). PMID: 39941765
Background/objectives: Radical prostatectomy (RP) may be considered for recurrent prostate cancer (PCa) following primary curative-intended local therapy. The effect of different prior therapies on patient-reported outcome measures (PROMs) after RP...
2.
Incisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?
Mazzucato G, Falkenbach F, Ekrutt J, Kohler D, von Amsberg G, Cerruto M, et al.
Clin Exp Metastasis . 2025 Jan; 42(2):13. PMID: 39883215
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely...
3.
Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer
Wenzel M, Hoeh B, Siech C, Humke C, Welte M, Ahrens M, et al.
Urol Oncol . 2025 Jan; PMID: 39855961
Objective: Demographic changes will lead to higher proportions of metastatic hormone-sensitive (mHSPC) and castration resistant metastatic prostate cancer (mCRPC) patients with higher frailty index and multiple comorbidities. Materials And Methods:...
4.
Prostate-specific Membrane Antigen-radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment
Falkenbach F, Lischewski F, Knipper S, Koehler D, Karakiewicz P, Tian Z, et al.
Eur Urol Focus . 2025 Jan; PMID: 39843283
We analyzed data for a cohort of 111 patients with EMBARK-like biochemical recurrence (BCR) of prostate cancer (prostate-specific antigen [PSA] doubling time ≤9 mo, PSA ≥1 ng/ml) after radical prostatectomy...
5.
Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen-targeted Radioguided Surgery for Oligorecurrent Prostate Cancer
Falkenbach F, Mazzucato G, Tian Z, Karakiewicz P, Graefen M, Steuber T, et al.
Eur Urol Open Sci . 2025 Jan; 70():1-7. PMID: 39822239
Background And Objective: In patients with oligorecurrent prostate cancer (PCa), prostate-specific membrane antigen-targeted radioguided surgery (PSMA-RGS) prolongs treatment-free survival. Data on patient-reported outcome measures (PROMs) are lacking. Methods: A retrospective...
6.
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy
Wenzel M, Hoeh B, Siech C, Koll F, Humke C, Groener D, et al.
Eur J Nucl Med Mol Imaging . 2025 Jan; PMID: 39804375
Purpose: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in...
7.
Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
Wenzel M, Hoeh B, Humke C, Garcia C, Siech C, Steuber T, et al.
World J Urol . 2024 Dec; 43(1):51. PMID: 39731623
Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the...
8.
Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer
Wenzel M, Hoeh B, Humke C, Welte M, Garcia C, Siech C, et al.
JBMR Plus . 2024 Dec; 9(1):ziae157. PMID: 39677923
Hormonal agents administered for metastatic castration-resistant prostate cancer (mCRPC) may lead to osteoporosis, skeletal events, reduced quality of life, and even reduced overall survival (OS). Bone-modifying agents may prevent those...
9.
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data
Hoeh B, Wenzel M, Tian Z, Karakiewicz P, Saad F, Steuber T, et al.
Eur Urol Focus . 2024 Dec; PMID: 39643549
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has been extended by another phase 3 randomized control trial (ARANOTE) demonstrating favorable outcomes of a doublet therapy combining the androgen...
10.
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy
Wenzel M, Koll F, Hoeh B, Humke C, Reis H, Wild P, et al.
JCO Precis Oncol . 2024 Dec; 8:e2400645. PMID: 39642328
Purpose: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC). The individual response to 177-lutetium prostate specific membrane antigen radioligand therapy (Lu-PSMA) is under current investigation regarding...